Table 1 Clinical characteristics of 22 HHT-patients and 20 healthy controls
Controls (n = 20) | HHT-patients (n = 22) | |
|---|---|---|
Female sex, n (%) | 11 (55%) | 10 (45%) |
Years, median age (IQR) | 54 (40–62) | 61 (50–72) |
Smoking, n (%) | 1 (5%) | 5 (22.7%) |
Co-morbidity | ||
Hypertension | 0 (0%) | 6 (27%) |
Diabetes mellitus II | 0 (0%) | 3 (13.6%) |
Systemic inflammatory disease | 0 (0%) | 4 (18%) |
Medical treatment | ||
Iron treatment (pill/infusion) | 0 | 9 (40%)/3 (13.3%) |
SSRI | 0 | 1 (4.5%) |
NSAID | 0 | 0 |
Tranexamic acid | 0 | 6 (26.6%) |
Platelet inhibitors | 0 | 3 (13.3%) |
Avastin | 0 | 0 |
Iron replacement therapy | 0 | 12 |
Blood transfusions within the last 4 weeks | 0 | 2 |
Electrocoagulation of nasal mucosa within last 4 weeks | 0 | 3 |
HHT-type, n (%) | ||
Type 1 | 12 (54.5%) | |
Type 2 | 10 (45.5%) | |
Epistaxis severity score (ESS), median (IQR) | 6 (5–6.5) | |
Arteriovenous malformations | ||
PAVM | 9 (40%) 5 needed further embolization | |
CAVM | 1 (5%) | |
HAVM | 5 (23%) | |